The New England journal of medicine
-
Editorial Comment
The Challenge of Respiratory Syncytial Virus Human Challenge Studies.
-
Randomized Controlled Trial Multicenter Study
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor. ⋯ Axi-cel therapy led to significant improvements, as compared with standard care, in event-free survival and response, with the expected level of high-grade toxic effects. (Funded by Kite; ZUMA-7 ClinicalTrials.gov number, NCT03391466.).
-
Randomized Controlled Trial
EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
Respiratory syncytial virus (RSV) infection causes substantial morbidity and mortality among infants, older adults, and immunocompromised adults. EDP-938, a nonfusion replication inhibitor of RSV, acts by modulating the viral nucleoprotein. ⋯ All EDP-938 regimens were superior to placebo with regard to lowering of the viral load, total symptom scores, and mucus weight without apparent safety concerns. (ClinicalTrials.gov number, NCT03691623.).